Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway
The protein lysine methyltransferase SMYD2 has recently emerged as a new enzyme modulate gene transcription or signaling pathways, and involved into tumor progression. However, the role of SMYD2 in drug resistant is still not known. Here, we found that inhibition of SMYD2 by specific inhibitor could...
Main Authors: | Lei Shang, Minjie Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00306/full |
Similar Items
-
Smyd2 conformational changes in response to p53 binding: role of the C‐terminal domain
by: Balasubramanian Chandramouli, et al.
Published: (2019-06-01) -
Inhibition of TIGAR Increases Exogenous p53 and Cisplatin Combination Sensitivity in Lung Cancer Cells by Regulating Glycolytic Flux
by: Jiaying Fu, et al.
Published: (2022-12-01) -
Pharmacological inhibition of SMYD2 protects against cisplatin-induced acute kidney injury in mice
by: Binbin Cui, et al.
Published: (2022-08-01) -
Targeting Epigenetic Changes Mediated by Members of the SMYD Family of Lysine Methyltransferases
by: Alyssa Padilla, et al.
Published: (2023-02-01) -
p53 in Proximal Tubules Mediates Chronic Kidney Problems after Cisplatin Treatment
by: Shuangshuang Fu, et al.
Published: (2022-02-01)